Patent Analyzer

Patent Analyzer — IP Landscape and Risk Assessment

Patent protection determines how long a drug generates premium revenue before generic or biosimilar competition erodes pricing power. For biotech venture investors, patent life is the single largest determinant of the revenue tail in rNPV models. A composition-of-matter patent expiring in 2038 vs 2031 can mean the difference between a $2B and $800M rNPV. Yet patent analysis in biotech diligence is often superficial — "they have patents until 2035" — without examining patent type, vulnerability to challenge, or freedom-to-operate risk.

This skill provides the methodology for rigorous patent landscape analysis.

LOE precedents & statutory clocks: exclusivity terms, patent-life math, and verified generic/biosimilar erosion precedents are in references/loe-precedents.md; full erosion curves in market-dynamics' launch-and-erosion-benchmarks.md.

How to Run

Input

Steps

Step 1 — Patent Type Taxonomy

Not all patents are equal. Classify each patent by type and assess its protective strength:

Assessment rule: An asset protected only by method-of-use and dosing patents (no CoM) faces significantly higher generic entry risk. A strong IP estate has CoM as the anchor with formulation and method-of-use as reinforcement.

Step 2 — Patent Life Calculation

Calculate effective patent life from filing date through all adjustments:

PATENT LIFE CALCULATION

Base Term:
  Filing date: [date]
  Base expiry: Filing + 20 years = [date]

Patent Term Adjustment (PTA) — 35 USC 271:
  USPTO prosecution delay: +[X] days
  Applicant delay offset: -[X] days
  Net PTA: +[X] days → Adjusted expiry: [date]

Patent Term Extension (PTE) — 35 USC 156:
  Eligible? [Y/N — only one patent per product; must be first commercial use]
  Regulatory review period: [X] months
  PTE = 50% of clinical testing time + 100% of regulatory review time
  Maximum PTE: 5 years
  Cannot extend total patent life beyond 14 years from approval
  PTE grant: +[X] months → PTE-adjusted expiry: [date]

Supplementary Protection Certificate (SPC) — EU:
  Duration: Time between patent filing and marketing authorization - 5 years
  Maximum: 5 years (+ 6 months with pediatric extension)
  SPC expiry: [date]

Effective Patent Expiry: [latest of US/EU dates]

Step 3 — Orange Book / Purple Book Analysis

Small Molecules — Orange Book (FDA):

The Orange Book lists patents and exclusivities for approved drugs. Analyze:

• Listed patents: Which patents are listed? CoM, formulation, method of use?
• Use codes: What specific indications are patent-protected?
• Exclusivity codes:
  • NCE (New Chemical Entity): 5 years — no ANDA filing permitted
  • New Clinical Investigation: 3 years — ANDAs can be filed but not approved
  • Orphan Drug: 7 years — no approval of same drug for same indication
  • Pediatric: +6 months added to all existing exclusivities and patents
  • QIDP (Qualified Infectious Disease Product): +5 years added to exclusivity
  • 180-day First Filer Exclusivity: First Paragraph IV filer gets 180 days generic exclusivity

Biologics — Purple Book (FDA):

• Reference product listing: Is the asset listed as a reference product?
• Biosimilar applications: Any 351(k) applications filed?
• Interchangeability: Any interchangeable biosimilar approved?
• BPCIA exclusivity:
  • 12-year data exclusivity from first licensure (no biosimilar approval)
  • 4-year filing exclusivity (no biosimilar application accepted)
  • First interchangeable biosimilar: 1 year market exclusivity

Step 4 — Paragraph IV / Patent Challenge Assessment

For small molecules, assess vulnerability to Paragraph IV (generic) challenge:

Paragraph IV Risk Factors:

30-Month Stay: When a Paragraph IV certification is filed, the brand gets an automatic 30-month stay of FDA approval while litigation proceeds. This stay is critical — it provides ~2.5 years of protected revenue even if the patent is ultimately invalidated.

Authorized Generic Strategy: Companies can launch an authorized generic (AG) at patent expiry or upon Paragraph IV loss to capture generic market share and reduce the economic incentive for independent generics.

Step 5 — Biosimilar Entry Analysis (BPCIA)

For biologics, model the biosimilar entry timeline:

BIOSIMILAR ENTRY TIMELINE

12-Year Exclusivity Clock:
  BLA approval date: [date]
  4-year mark (earliest biosimilar filing): [date]
  12-year mark (earliest biosimilar approval): [date]

Patent Dance (BPCIA):
  Phase 1: Biosimilar applicant provides application + manufacturing info
  Phase 2: Reference product sponsor identifies relevant patents
  Phase 3: Negotiation of patents for immediate litigation
  Phase 4: Litigation on agreed patents
  Phase 5: Remaining patents available for later litigation

Practical Biosimilar Entry:
  Earliest possible: 12-year exclusivity expiry
  Most likely: 12 years + 2-4 years (patent litigation resolution)
  Delayed: Key CoM patent extends beyond 12-year exclusivity

Interchangeability impact: An interchangeable biosimilar can be substituted at the pharmacy without physician intervention, accelerating erosion dramatically. Non-interchangeable biosimilars require physician prescribing, slowing switching.

Step 6 — Patent Thicket Assessment

A "patent thicket" is a dense web of overlapping patents designed to extend effective exclusivity beyond the core CoM patent:

PATENT THICKET ANALYSIS

Total patents listed: [N]
Patent types:
  Composition of Matter: [N]  (expiry: [dates])
  Formulation:           [N]  (expiry: [dates])
  Method of Use:         [N]  (expiry: [dates])
  Dosing:                [N]  (expiry: [dates])
  Process:               [N]  (expiry: [dates])
  Combination:           [N]  (expiry: [dates])

Latest expiring patent: [date]
Earliest vulnerable entry: [date — when generics could enter with skinny label]
Effective exclusivity extension from thicket: [years beyond CoM expiry]

Thicket strength: [Strong / Moderate / Weak]
  Strong: Multiple overlapping types with staggered expiries; no skinny label path
  Moderate: Some protection beyond CoM but skinny label path exists
  Weak: CoM is the only meaningful barrier; ancillary patents easily designed around

Step 7 — Freedom-to-Operate (FTO) Analysis

Assess whether the asset infringes third-party patents:

FTO risk levels:

• Clean FTO: No identified third-party patent risks; freedom to develop and commercialize
• Encumbered FTO: Known patent risks requiring license or design-around; quantify royalty exposure (typically 2-8% of net sales)
• Blocked FTO: Third-party patent directly covers the asset; license is mandatory or development must halt

Output

PATENT LANDSCAPE ANALYSIS — [Asset Name]
Date: [assessment date]

PATENT ESTATE SUMMARY:
| Patent # | Type | Filing Date | Expiry | PTE/PTA | Effective Expiry | Strength |
|----------|------|-------------|--------|---------|------------------|----------|
| US X,XXX | CoM  | [date]      | [date] | +[X]mo  | [date]           | Strong   |
| US X,XXX | MoU  | [date]      | [date] | N/A     | [date]           | Moderate |
| ...      |      |             |        |         |                  |          |

KEY DATES:
  Loss of Exclusivity (LOE): [date]
  Earliest generic/biosimilar entry: [date]
  Latest patent expiry: [date]
  Effective IP protection remaining: [X] years

PATENT THICKET: [Strong / Moderate / Weak]
FTO ASSESSMENT: [Clean / Encumbered / Blocked]
  Royalty exposure (if encumbered): [X]% of net sales

GENERIC/BIOSIMILAR ENTRY RISK:
  Timeline: [X] years from now
  Likelihood within 5 years: [Low / Moderate / High]
  Entry impact on revenue: [X]% erosion over [X] years

OVERALL IP RISK RATING: [Low / Moderate / High / Critical]

Error Handling

Cross-Domain Connections

• manufacturing-ip/ip-valuation: Patent life directly determines IP value and revenue tail
• asset-valuation/rnpv-modeler: Patent expiry sets the revenue cutoff in rNPV models
• competitive-intelligence/market-dynamics: LOE timing determines biosimilar/generic erosion curve
• regulatory-strategy: Regulatory exclusivity interacts with patent protection (may extend or be redundant)
• deal-synthesis/diligence-scorecard: IP assessment feeds Pillar 5 (IP Fortress) of the 8-pillar scorecard